BRAF突变-话题@MedSci

#BRAF突变#

30篇内容 | 2138人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1480712, encodeId=7b3a1480e123e, content=<a href='/topic/show?id=e76836e150' target=_blank style='color:#2F92EE;'>#BRAF突变#</a>, objectTitle=JAMA Oncology：RAS和BRAF突变Ⅲ期结肠癌患者肿瘤位置的预后价值, objectType=article, longId=121370, objectId=943f1213e0f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=943f1213e0f9, replyNumber=0, likeNumber=95, createdTime=2017-11-27, rootId=0, userName=ms4964546379600229, userId=eff97667327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=943f1213e0f9, moduleTitle=JAMA Oncology：RAS和BRAF突变Ⅲ期结肠癌患者肿瘤位置的预后价值, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=943f1213e0f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1480711, encodeId=4ba01480e1174, content=<a href='/topic/show?id=e76836e150' target=_blank style='color:#2F92EE;'>#BRAF突变#</a>, objectTitle=Lancet Oncol：为Braf突变的晚期肺癌患者提供一条新的诊疗思路, objectType=article, longId=117266, objectId=39cc11e26686, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39cc11e26686, replyNumber=0, likeNumber=85, createdTime=2017-10-25, rootId=0, userName=ms4964546379600229, userId=eff97667327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39cc11e26686, moduleTitle=Lancet Oncol：为Braf突变的晚期肺癌患者提供一条新的诊疗思路, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39cc11e26686)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1480710, encodeId=5ade1480e1090, content=<a href='/topic/show?id=e76836e150' target=_blank style='color:#2F92EE;'>#BRAF突变#</a>, objectTitle=CLIN CANCER RES：Encorafenib治疗BRAF突变转移性黑色素瘤, objectType=article, longId=113271, objectId=d1101132e1b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d1101132e1b4, replyNumber=0, likeNumber=92, createdTime=2017-09-21, rootId=0, userName=ms4964546379600229, userId=eff97667327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d1101132e1b4, moduleTitle=CLIN CANCER RES：Encorafenib治疗BRAF突变转移性黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d1101132e1b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1480709, encodeId=89201480e09e3, content=<a href='/topic/show?id=e76836e150' target=_blank style='color:#2F92EE;'>#BRAF突变#</a>, objectTitle=J Clin OncoL:BRAF突变mCRC再细分，新突变亚型引人瞩目, objectType=article, longId=108813, objectId=a8b410881330, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8b410881330, replyNumber=0, likeNumber=99, createdTime=2017-08-16, rootId=0, userName=ms4964546379600229, userId=eff97667327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8b410881330, moduleTitle=J Clin OncoL:BRAF突变mCRC再细分，新突变亚型引人瞩目, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8b410881330)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1480708, encodeId=d53b1480e08b2, content=<a href='/topic/show?id=e76836e150' target=_blank style='color:#2F92EE;'>#BRAF突变#</a>, objectTitle=Ann Oncol :BRAF突变结直肠癌的诊治现状与展望, objectType=article, longId=107461, objectId=1a7c10e4613d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a7c10e4613d, replyNumber=0, likeNumber=64, createdTime=2017-08-03, rootId=0, userName=ms4964546379600229, userId=eff97667327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a7c10e4613d, moduleTitle=Ann Oncol :BRAF突变结直肠癌的诊治现状与展望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a7c10e4613d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1480707, encodeId=fa5e1480e077d, content=<a href='/topic/show?id=e76836e150' target=_blank style='color:#2F92EE;'>#BRAF突变#</a>, objectTitle=Oncologist：BRAF突变NSCLC靶向治疗研究现状, objectType=article, longId=99268, objectId=c6c099268bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6c099268bd, replyNumber=0, likeNumber=89, createdTime=2017-05-22, rootId=0, userName=ms4964546379600229, userId=eff97667327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6c099268bd, moduleTitle=Oncologist：BRAF突变NSCLC靶向治疗研究现状, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c6c099268bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1480706, encodeId=27d81480e06ea, content=<a href='/topic/show?id=e76836e150' target=_blank style='color:#2F92EE;'>#BRAF突变#</a>, objectTitle=JCO：Non-V600 BRAF突变应成为转移性结直肠癌新的临床亚型, objectType=article, longId=98591, objectId=5f7798591ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f7798591ca, replyNumber=0, likeNumber=80, createdTime=2017-05-14, rootId=0, userName=ms4964546379600229, userId=eff97667327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f7798591ca, moduleTitle=JCO：Non-V600 BRAF突变应成为转移性结直肠癌新的临床亚型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f7798591ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1480705, encodeId=a1711480e056b, content=<a href='/topic/show?id=e76836e150' target=_blank style='color:#2F92EE;'>#BRAF突变#</a>, objectTitle=Oncogene：PDE4D促进BRAF突变黑色素瘤中FAK介导的细胞侵袭, objectType=article, longId=88059, objectId=613888059d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=613888059d5, replyNumber=0, likeNumber=82, createdTime=2017-01-26, rootId=0, userName=ms4964546379600229, userId=eff97667327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=613888059d5, moduleTitle=Oncogene：PDE4D促进BRAF突变黑色素瘤中FAK介导的细胞侵袭, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=613888059d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1480704, encodeId=30731480e0436, content=<a href='/topic/show?id=e76836e150' target=_blank style='color:#2F92EE;'>#BRAF突变#</a>, objectTitle=Cell Reports: 致癌基因BRAF突变介导了黑色素瘤的侵袭, objectType=article, longId=69564, objectId=546a69564fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=546a69564fb, replyNumber=0, likeNumber=78, createdTime=2016-06-02, rootId=0, userName=ms4964546379600229, userId=eff97667327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=546a69564fb, moduleTitle=Cell Reports: 致癌基因BRAF突变介导了黑色素瘤的侵袭, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=546a69564fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1480703, encodeId=7f621480e03c4, content=<a href='/topic/show?id=e76836e150' target=_blank style='color:#2F92EE;'>#BRAF突变#</a>, objectTitle=喜大普奔！BRAF突变的黑色素瘤患者生存希望增加！, objectType=article, longId=58793, objectId=e0d658e93be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0d658e93be, replyNumber=0, likeNumber=83, createdTime=2015-11-15, rootId=0, userName=ms4964546379600229, userId=eff97667327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0d658e93be, moduleTitle=喜大普奔！BRAF突变的黑色素瘤患者生存希望增加！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0d658e93be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1480702, encodeId=235e1480e026b, content=<a href='/topic/show?id=e76836e150' target=_blank style='color:#2F92EE;'>#BRAF突变#</a>, objectTitle=Lancet：dabrafenib和trametinib联合治疗Val6000 BRAF突变的黑色素瘤, objectType=article, longId=51556, objectId=04735155643, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04735155643, replyNumber=0, likeNumber=99, createdTime=2015-06-04, rootId=0, userName=ms4964546379600229, userId=eff97667327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04735155643, moduleTitle=Lancet：dabrafenib和trametinib联合治疗Val6000 BRAF突变的黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04735155643)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1480701, encodeId=8c311480e0108, content=<a href='/topic/show?id=e76836e150' target=_blank style='color:#2F92EE;'>#BRAF突变#</a>, objectTitle=JAMA Oncology：NRAS和BRAF突变与高危型原发黑色素瘤生存期的关系, objectType=article, longId=49384, objectId=e11b4938401, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e11b4938401, replyNumber=0, likeNumber=68, createdTime=2015-04-16, rootId=0, userName=ms4964546379600229, userId=eff97667327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e11b4938401, moduleTitle=JAMA Oncology：NRAS和BRAF突变与高危型原发黑色素瘤生存期的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e11b4938401)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1480700, encodeId=78691480e006c, content=<a href='/topic/show?id=e76836e150' target=_blank style='color:#2F92EE;'>#BRAF突变#</a>, objectTitle=Lancet Oncol：威罗非尼改善BRAF突变黑色素瘤患者生存, objectType=article, longId=31709, objectId=877631e09af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=877631e09af, replyNumber=0, likeNumber=54, createdTime=2014-03-12, rootId=0, userName=ms4964546379600229, userId=eff97667327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=877631e09af, moduleTitle=Lancet Oncol：威罗非尼改善BRAF突变黑色素瘤患者生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=877631e09af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1480699, encodeId=4c541480699d3, content=<a href='/topic/show?id=e76836e150' target=_blank style='color:#2F92EE;'>#BRAF突变#</a>, objectTitle=【ASCO 2012】两大新药治疗BRAF突变黑色素瘤疗效显著, objectType=article, longId=6937, objectId=3636693e14, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3636693e14, replyNumber=0, likeNumber=72, createdTime=2012-06-11, rootId=0, userName=ms4964546379600229, userId=eff97667327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3636693e14, moduleTitle=【ASCO 2012】两大新药治疗BRAF突变黑色素瘤疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3636693e14)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1480698, encodeId=6188148069820, content=<a href='/topic/show?id=e76836e150' target=_blank style='color:#2F92EE;'>#BRAF突变#</a>, objectTitle=Trametinib和Dabrafenib对BRAF突变黑色素瘤疗效优于化疗, objectType=article, longId=6885, objectId=1fc1688510, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1fc1688510, replyNumber=0, likeNumber=0, createdTime=2012-06-09, rootId=0, userName=ms4964546379600229, userId=eff97667327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1fc1688510, moduleTitle=Trametinib和Dabrafenib对BRAF突变黑色素瘤疗效优于化疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1fc1688510)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

BRAF突变

2020-05-29

ms4964546379600229 (审核中...)

前往app查看评论内容

#BRAF突变#

JAMA Oncology：RAS和BRAF突变Ⅲ期结肠癌患者肿瘤位置的预后价值

2017-11-27

ms4964546379600229 (审核中...)

前往app查看评论内容

#BRAF突变#

Lancet Oncol：为Braf突变的晚期肺癌患者提供一条新的诊疗思路

2017-10-25

ms4964546379600229 (审核中...)

前往app查看评论内容

#BRAF突变#

CLIN CANCER RES：Encorafenib治疗BRAF突变转移性黑色素瘤

2017-09-21

ms4964546379600229 (审核中...)

前往app查看评论内容

#BRAF突变#

J Clin OncoL:BRAF突变mCRC再细分，新突变亚型引人瞩目

2017-08-16

ms4964546379600229 (审核中...)

前往app查看评论内容

#BRAF突变#

Ann Oncol :BRAF突变结直肠癌的诊治现状与展望

2017-08-03

ms4964546379600229 (审核中...)

前往app查看评论内容

#BRAF突变#

Oncologist：BRAF突变NSCLC靶向治疗研究现状

2017-05-22

ms4964546379600229 (审核中...)

前往app查看评论内容

#BRAF突变#

JCO：Non-V600 BRAF突变应成为转移性结直肠癌新的临床亚型

2017-05-14

ms4964546379600229 (审核中...)

前往app查看评论内容

#BRAF突变#

Oncogene：PDE4D促进BRAF突变黑色素瘤中FAK介导的细胞侵袭

2017-01-26

ms4964546379600229 (审核中...)

前往app查看评论内容

#BRAF突变#

Cell Reports: 致癌基因BRAF突变介导了黑色素瘤的侵袭

2016-06-02

ms4964546379600229 (审核中...)

前往app查看评论内容

#BRAF突变#

喜大普奔！BRAF突变的黑色素瘤患者生存希望增加！

2015-11-15

ms4964546379600229 (审核中...)

前往app查看评论内容

#BRAF突变#

Lancet：dabrafenib和trametinib联合治疗Val6000 BRAF突变的黑色素瘤

2015-06-04

ms4964546379600229 (审核中...)

前往app查看评论内容

#BRAF突变#

JAMA Oncology：NRAS和BRAF突变与高危型原发黑色素瘤生存期的关系

2015-04-16

ms4964546379600229 (审核中...)

前往app查看评论内容

#BRAF突变#

Lancet Oncol：威罗非尼改善BRAF突变黑色素瘤患者生存

2014-03-12

ms4964546379600229 (审核中...)

前往app查看评论内容

#BRAF突变#

【ASCO 2012】两大新药治疗BRAF突变黑色素瘤疗效显著

2012-06-11

ms4964546379600229 (审核中...)

前往app查看评论内容

#BRAF突变#

Trametinib和Dabrafenib对BRAF突变黑色素瘤疗效优于化疗

2012-06-09

科室
- - 订阅+
  - 更多科室
工具
服务